Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STELLA: Donor-Derived MultiTAA-Specific T Cells for ALL
NCT02475707Phase 1Completed
- Sponsor
- Baylor College of Medicine
- Start
- Feb 2016
- Primary completion
- Oct 2019
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of multiTAA-specific T cells in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Baylor College of Medicine. Primary endpoint: Number of patients with dose-limiting toxicities at 4 weeks. Started Feb 2016; status: completed.
02
Drugs
multiTAA-specific T cells
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02475707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02475707.